Former “String Of Pearls” Strategist Tabbed To Lead Teva’s Continuing Diversification

Jeremy Levin, who left Bristol-Myers Squibb on Jan. 1, will succeed outgoing Teva CEO Shlomo Yanai in May, as the Israeli generics giant seeks to increase its emphasis on branded drugs.